Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $37.3333.

A number of brokerages have weighed in on NBTX. Guggenheim boosted their price target on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Finally, Leerink Partners boosted their price target on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th.

Hedge Funds Weigh In On Nanobiotix

Several institutional investors and hedge funds have recently made changes to their positions in NBTX. Optiver Holding B.V. acquired a new position in shares of Nanobiotix in the third quarter valued at approximately $101,000. Marshall Wace LLP acquired a new position in shares of Nanobiotix in the fourth quarter valued at approximately $220,000. Royal Bank of Canada grew its position in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Nanobiotix in the fourth quarter valued at approximately $390,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Price Performance

Shares of NASDAQ NBTX opened at $35.54 on Friday. The business’s 50 day moving average price is $37.63 and its two-hundred day moving average price is $29.41. Nanobiotix has a twelve month low of $4.18 and a twelve month high of $57.14.

Nanobiotix (NASDAQ:NBTX) last announced its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $3.42 million during the quarter. As a group, equities research analysts expect that Nanobiotix will post 0.19 EPS for the current fiscal year.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.